The eyes in diabetes and diabetes through the eyes

被引:9
作者
Harman-Boehm, Ilana [1 ,2 ]
Sosna, Tomas [3 ]
Lund-Andersen, Henrik [4 ,5 ]
Poita, Massimo [6 ]
机构
[1] Soroka Univ, Med Ctr, Dept Internal Med C, Beer Sheva, Israel
[2] Soroka Univ, Med Ctr, Diabet Unit, Beer Sheva, Israel
[3] IKEM, Cent Diabetol, Prague, Czech Republic
[4] Univ Dept Herlev Hosp, Copenhagen, Denmark
[5] Steno Diabet Ctr, Copenhagen, Denmark
[6] Univ Turin, Turin, Italy
关键词
diabetic retinopathy; protein kinase C; renin-angiotensin system; microvascular complications; AGE; polyols;
D O I
10.1016/j.diabres.2007.09.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic retinopathy (DR) is the most common of the microvascular complications of diabetes. Left unchecked and untreated, it could progresses from a non-proliferative phase to a proliferative, sight-threatening phase. Macular edema which also threatens sight can appear at any stage. The pathophysiological mechanisms underlying its appearance and progression include the accumulation of plyols, advanced glycation endproducts (AGE) reactive oxygen species, release of local growth factors and activation of protein kinase C, all of which lead to structural and functional changes in the retina which can progress to threaten sight. Tight glucose and blood pressure control can prevent the appearance and progression of retinopathy. Novel PKC inhibitors, inhibitors of growth factors, blockers of the renin-angiotensin system (RAS) as well as statins can slow the progression of DR and protect sight. (c) 2007 Published by Elsevier Ireland Ltd.
引用
收藏
页码:S51 / S58
页数:8
相关论文
共 49 条
[41]   Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization [J].
Soliman, Wael ;
Lund-Andersen, Henrik ;
Larsen, Michael .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2006, 84 (05) :707-708
[42]  
Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
[43]   UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis [J].
Stratton, IM ;
Kohner, EM ;
Aldington, SJ ;
Turner, RC ;
Holman, RR ;
Manley, SE ;
Matthews, DR .
DIABETOLOGIA, 2001, 44 (02) :156-163
[44]   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].
Turner, RC ;
Holman, RR ;
Cull, CA ;
Stratton, IM ;
Matthews, DR ;
Frighi, V ;
Manley, SE ;
Neil, A ;
McElroy, K ;
Wright, D ;
Kohner, E ;
Fox, C ;
Hadden, D ;
Mehta, Z ;
Smith, A ;
Nugent, Z ;
Peto, R ;
Adlel, AI ;
Mann, JI ;
Bassett, PA ;
Oakes, SF ;
Dornan, TL ;
Aldington, S ;
Lipinski, H ;
Collum, R ;
Harrison, K ;
MacIntyre, C ;
Skinner, S ;
Mortemore, A ;
Nelson, D ;
Cockley, S ;
Levien, S ;
Bodsworth, L ;
Willox, R ;
Biggs, T ;
Dove, S ;
Beattie, E ;
Gradwell, M ;
Staples, S ;
Lam, R ;
Taylor, F ;
Leung, L ;
Carter, RD ;
Brownlee, SM ;
Fisher, KE ;
Islam, K ;
Jelfs, R ;
Williams, PA ;
Williams, FA ;
Sutton, PJ .
LANCET, 1998, 352 (9131) :837-853
[45]   Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy [J].
van Buggenum, IMH ;
Polak, BCP ;
Reichert-Thoen, JWM ;
de Vries-Knoppert, WAEJ ;
van Hinsbergh, VWM ;
Tangelder, GJ .
DIABETOLOGIA, 2002, 45 (02) :203-209
[46]   Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular oedema [J].
Vinten, Martin ;
Larsen, Michael ;
Lund-Andersen, Henrik ;
Sander, Birgit ;
La Cour, Morten .
ACTA OPHTHALMOLOGICA SCANDINAVICA, 2007, 85 (01) :21-26
[47]  
Warnold I, 2005, J RENIN-ANGIO-ALDO S, V6, P25
[48]   The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy [J].
Wilkinson-Berka, Jennifer L. ;
Wraight, Christopher ;
Werther, George .
CURRENT MEDICINAL CHEMISTRY, 2006, 13 (27) :3307-3317
[49]   Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control [J].
Zhang, LY ;
Krzentowski, G ;
Albert, A ;
Lefebvre, PJ .
DIABETES CARE, 2001, 24 (07) :1275-1279